IgG1 monoclonal antibody targeting CD38; induces ADCC, CDC, and direct apoptosis of myeloma cells.
Humanized IgG1 monoclonal antibody against CD38 that binds CD38 on myeloma cells and induces antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptotic signaling, leading to lysis of CD38-expressing tumor cells.
Isatuximab binds CD38 on target cells and induces killing via ADCC (NK cell–mediated), CDC (complement), and direct pro-apoptotic signaling, leading to lysis of CD38-expressing cells.
Autologous, gene-modified T cells engineered to express a CAR targeting CD19 on malignant B cells, inducing T-cell activation and cytotoxic killing of tumor cells.
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD19 on B cells; upon antigen engagement, CAR signaling (CD3ζ with costimulatory domains such as CD28 or 4‑1BB) activates the T cells to proliferate, secrete cytokines, and mediate cytotoxic killing of CD19‑positive malignant B cells.
CAR T cells recognize CD19 and directly kill CD19+ cells via T-cell cytotoxicity (perforin/granzyme release and Fas–FasL–mediated apoptosis).
Humanized IgG1 monoclonal antibody targeting TIGIT to block TIGIT–CD155 signaling and enhance anti-tumor immunity; Fcγ-engaging checkpoint inhibitor.
Humanized IgG1 monoclonal antibody against TIGIT that blocks TIGIT–CD155 (and CD112) interactions, relieving inhibitory signaling on T and NK cells to restore anti-tumor activity; the Fcγ-engaging IgG1 can recruit effector functions (e.g., ADCC/ADCP) against TIGIT-expressing cells.
Anti-TIGIT IgG1 binds TIGIT on cells and engages Fcγ receptors on NK cells/macrophages to mediate ADCC/ADCP (and potentially CDC), depleting TIGIT-expressing cells.
Investigational intravenous bispecific antibody immunotherapy (immune-cell engager) that binds Claudin-6 on tumor cells and an immune effector cell receptor to trigger immune-mediated killing of CLDN6-positive cancers.
ASP1893 is an investigational bispecific antibody that binds Claudin‑6 on tumor cells and a receptor on T cells (e.g., CD3), bringing T cells into close proximity to CLDN6‑positive tumor cells to trigger T‑cell activation and cytotoxic killing.
Bispecific antibody engages CD3 on T cells and CLDN6 on tumor cells, forming an immune synapse that activates T cells to kill CLDN6+ cells via perforin/granzyme–mediated apoptosis.
An anti-PSMA monoclonal antibody that binds prostate-specific membrane antigen (FOLH1) on prostate cancer cells; upon binding and internalization, it enables tumor-targeted uptake of the attached radionuclide for imaging and potential cytotoxicity.
NY108 is a PSMA (FOLH1)-targeted monoclonal antibody linked to lutetium-177. After binding PSMA on prostate cancer cells and being internalized, it delivers tumor-targeted beta radiation that can induce cytotoxic DNA damage, while its gamma emissions enable SPECT imaging of biodistribution.
An anti-PSMA monoclonal antibody delivers lutetium-177 to PSMA-expressing cells; internalization concentrates beta radiation that induces DNA double-strand breaks leading to cell death (with some crossfire to nearby cells).